#1 Clinical Trials Search in Europe

Specific Nucleic Acid Sna-Her1

A new clinical trial is underway to assess the effectiveness of 2LHERP®, a drug containing specific nucleic acids, in treating recurrent orofacial herpes infections, commonly known as cold sores. This randomized, placebo-controlled, double-blind study aims to determine if 2LHERP® can reduce the frequency and severity of cold sore outbreaks in patients who experience frequent episodes. The trial will evaluate various aspects of the treatment’s efficacy and its impact on patients’ quality of life over a 12-month period.

Table of Contents

What is 2LHERP?

2LHERP is a new medication being studied for the treatment of recurrent cold sores, also known as orofacial herpes infections[1]. It comes in the form of granules in capsules that are meant to be opened before use[1]. The medication is applied to the mouth and surrounding areas (oromucosal use)[1].

How Does 2LHERP Work?

2LHERP contains several active ingredients that are types of nucleic acids. These include[1]:

  • Deoxyribonucleic acid (DNA): The genetic material found in all living organisms
  • Ribonucleic acid (RNA): A molecule similar to DNA that plays various roles in biological processes
  • Specific Nucleic Acid SNA-HER1: Also known as “Specific Nucleic Acid – Herpes Simplex Type I Virus”
  • Specific Nucleic Acid SNA-HER2: Also known as “Specific Nucleic Acid – Herpes Simplex Type II Virus”
  • Specific Nucleic Acid SNA-HLA I: Also known as “Specific Nucleic Acid – Human Leucocyte Antigen Type I”
  • Specific Nucleic Acid SNA-HLA II: Also known as “Specific Nucleic Acid – Human Leucocyte Antigen Type II”

These specific nucleic acids are designed to target the herpes simplex virus and potentially help the immune system fight against cold sore outbreaks. However, the exact mechanism of action is still being studied in clinical trials[1].

What Conditions Does 2LHERP Treat?

2LHERP is being studied for the treatment of recurrent orofacial herpes infections, commonly known as cold sores or fever blisters[1]. These are painful, fluid-filled blisters that typically appear on or around the lips and are caused by the herpes simplex virus. The medication is specifically being tested in patients who experience frequent outbreaks, defined as 6 or more episodes within a 12-month period[1].

Clinical Trial Details

A clinical trial is currently being conducted to evaluate the effectiveness of 2LHERP[1]. This is a Phase IV clinical trial, which means the medication has already been approved for marketing, but more information is being gathered about its effects and optimal use[1].

The main goal of this trial is to see if 2LHERP can reduce the number of cold sore outbreaks over a 12-month period[1]. The study is designed as a randomized, placebo-controlled, double-blind trial. This means that participants will be randomly assigned to receive either 2LHERP or a placebo (a substance with no active ingredients), and neither the participants nor the researchers will know who is receiving which treatment until the study is complete[1].

Who Can Participate in the Trial?

The trial is looking for participants who meet the following criteria[1]:

  • Men or women aged 16-80 years
  • Have experienced 6 or more episodes of cold sores in the past 12 months
  • Women of childbearing age must be using effective contraception
  • Must be in a stable sexual relationship
  • Able to understand and follow the study requirements

Some factors that would prevent someone from participating include[1]:

  • Pregnancy or breastfeeding
  • Recent use of certain medications, including immunotherapy or antiviral therapy
  • Known lactose intolerance
  • Severe immunodeficiency diseases
  • Use of recreational drugs

What to Expect During the Trial

If you participate in the trial, you can expect the following[1]:

  • The study will last for 12 months
  • You will receive either 2LHERP or a placebo
  • The maximum daily dose of 2LHERP is 380 mg
  • The maximum total dose over the 6-month treatment period is 68.4 g
  • You will be asked to keep track of any cold sore outbreaks you experience
  • Researchers will assess various factors, including:
    • The number of cold sore episodes you have
    • How long each episode lasts
    • The severity of your symptoms
    • Whether you need to use any rescue medication
    • How the treatment affects your quality of life

Potential Benefits and Risks

The potential benefits of participating in this trial include[1]:

  • Possible reduction in the frequency of cold sore outbreaks
  • Contributing to the advancement of medical knowledge about cold sore treatments
  • Close monitoring of your condition by healthcare professionals

However, as with any medical treatment, there may be risks involved. The researchers will be monitoring for any adverse events or serious adverse events throughout the trial[1]. It’s important to discuss any concerns you have with the research team before agreeing to participate in the trial.

Aspect Details
Study Drug 2LHERP®
Main Active Substances Specific Nucleic Acids (SNA-HER1, SNA-HER2, SNA-HLA I, SNA-HLA II)
Target Condition Recurrent orofacial herpes infections (cold sores)
Primary Objective Reduce number of cold sore episodes over 12 months
Secondary Objectives Evaluate time to first recurrence, episode duration, symptom severity, need for rescue medication, quality of life impact, and safety
Study Design Randomized, placebo-controlled, double-blind
Study Duration 12 months
Participant Age Range 16-80 years
Key Inclusion Criteria 6+ cold sore episodes in past 12 months, stable sexual relationship
Key Exclusion Criteria Pregnancy, immunotherapy, recent antiviral therapy, severe immunodeficiency

FAQ

  • What is the main goal of this clinical trial? The main goal is to evaluate how effective 2LHERP® is in reducing the number of recurrent orofacial herpes (cold sore) episodes over a 12-month period.
  • Who can participate in this study? The study is open to men and women aged 16-80 years who have experienced 6 or more episodes of orofacial herpes infections in the 12 months before joining the study. Participants must also be in a stable sexual relationship and able to understand and follow the study requirements.
  • What will the study measure besides the number of cold sore episodes? The study will also look at how long it takes for the first cold sore to appear during treatment, how long each episode lasts, the severity of symptoms, the need for additional medication, the impact on quality of life, and any safety concerns.
  • How long will participants be involved in the study? Participants will be followed for a period of 12 months to assess the long-term effects of the treatment.
  • What is 2LHERP® and how is it administered? 2LHERP® is a drug that contains specific nucleic acids and is administered as granules in capsules that are meant to be opened. It is taken orally and is designed to target the herpes simplex virus that causes cold sores.

Ongoing Clinical Trials on Specific Nucleic Acid Sna-Her1

  • Study on the Effectiveness of 2LHERP in Reducing Recurrent Cold Sores in Patients with Frequent Outbreaks

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Orofacial herpes: A viral infection caused by the herpes simplex virus that affects the face, particularly the mouth area, resulting in cold sores or fever blisters.
  • Randomized: A method used in clinical trials where participants are assigned by chance to different treatment groups, reducing bias in the study results.
  • Placebo-controlled: A study design where some participants receive an inactive substance (placebo) instead of the actual treatment, allowing researchers to compare the true effects of the drug being tested.
  • Double-blind: A study method where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving the placebo, helping to prevent bias in the results.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect under ideal circumstances.
  • Nucleic acid: A complex organic substance found in living cells, including DNA and RNA, which carry genetic information and instructions for cell function.
  • Recurrent: Something that occurs repeatedly or periodically, in this case referring to cold sore outbreaks that happen multiple times.
  • Immunotherapy: A type of treatment that uses the body's immune system to fight diseases, including some viral infections.
  • Antiviral therapy: Treatment using drugs specifically designed to treat viral infections by preventing the virus from multiplying or spreading.
  • Quality of life: A measure of an individual's overall well-being and satisfaction with life, including physical, mental, and social aspects.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lherp-in-reducing-recurrent-cold-sores-in-patients-with-frequent-outbreaks/